Home » Stocks » CERC

Cerecor Inc. (CERC)

Stock Price: $2.85 USD -0.05 (-1.72%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $2.96 +0.11 (3.86%) Jul 23, 7:59 PM
Market Cap 275.68M
Revenue (ttm) 4.42M
Net Income (ttm) -73.06M
Shares Out 89.10M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $2.85
Previous Close $2.90
Change ($) -0.05
Change (%) -1.72%
Day's Open 2.93
Day's Range 2.80 - 2.96
Day's Volume 199,129
52-Week Range 1.98 - 4.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Cerecor completes divestiture of non-core neurology pipeline assets as it increases its focus on immunology, immuno-oncology, and rare genetic disorders Cerecor completes divestiture of non-core neurolo...

1 month ago - GlobeNewsWire

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared ...

Other stocks mentioned: CRSP, HZNP, JNJ, LLY, SDGR, TAK
2 months ago - InvestorPlace

ROCKVILLE, Md. and CHESTERBROOK, Pa., May 13, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of t...

2 months ago - GlobeNewsWire

These 3 penny stocks made big moves in pre-market trading; are they worth it? The post Top Penny Stocks to Buy Moving in Premarket?

Other stocks mentioned: PHUN, PLIN
2 months ago - PennyStocks

The FDA has granted Fast Track designation to Cerecor Inc's (NASDAQ: CERC) CERC-002 to treat hospitalized patients with COVID-19. CERC-002 is a first-in-class fully human monoclonal antibody targeting L...

2 months ago - Benzinga

$230 million biopharmaceutical company Cerecor (CERC) may end up being the industry's biggest winner on Wall Street over the next six months. The post A Small Biotech Stock That Has All The Right Ingred...

2 months ago - InvestorPlace

Cerecor Inc's (NASDAQ: CERC) wholly-owned subsidiary, Aevi Genomic Medicine LLC, has entered into an expanded agreement with Kyowa Kirin Co Ltd (OTCMKTS: KYKOF) for exclusive worldwide rights to CERC-00...

3 months ago - Benzinga

ROCKVILLE, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare a...

3 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of tre...

4 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., March 04, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of...

4 months ago - GlobeNewsWire

Cerecor Inc (NASDAQ: CERC) shares gained premarket on the heels of final efficacy data, including 60-day mortality from the Phase 2 trial evaluating CERC-002 in hospitalized patients with COVID-19 assoc...

4 months ago - Benzinga

ROCKVILLE, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and or...

5 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor”; NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercializat...

6 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

6 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

6 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

6 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

7 months ago - GlobeNewsWire

Initial data anticipated in the first quarter of 2021 Initial data anticipated in the first quarter of 2021

7 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

7 months ago - GlobeNewsWire

ROCKVILLE, Md., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare an...

8 months ago - GlobeNewsWire

On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year end

8 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of trea...

9 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of t...

10 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of t...

10 months ago - GlobeNewsWire

The data strongly support Cerecor’s ongoing clinical study of CERC-002 as a novel potential treatment for COVID-19-related ARDS The data strongly support Cerecor’s ongoing clinical study of CERC-002 as ...

11 months ago - GlobeNewsWire

-Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement

11 months ago - GlobeNewsWire

ROCKVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric and...

11 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare...

11 months ago - GlobeNewsWire

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for rare...

11 months ago - GlobeNewsWire

Top-line Data Anticipated in Fourth Quarter 2020 Top-line Data Anticipated in Fourth Quarter 2020

1 year ago - GlobeNewsWire

ROCKVILLE, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pedi...

1 year ago - GlobeNewsWire

ROCKVILLE, Md., June 09, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pedi...

1 year ago - GlobeNewsWire

ROCKVILLE, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pedi...

1 year ago - GlobeNewsWire

-Appoints Sol J. Barer, Ph.D. as Chairman of the Board- Appoints Suzanne Bruhn, Ph.D. and Joseph Miller as Directors to the Board

1 year ago - GlobeNewsWire

ROCKVILLE, Md., March 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare ped...

1 year ago - GlobeNewsWire

ROCKVILLE, Md., March 06, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare ped...

1 year ago - GlobeNewsWire

-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases  -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer

1 year ago - GlobeNewsWire

-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases -Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical Officer ...

1 year ago - GlobeNewsWire

ROCKVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan di...

1 year ago - GlobeNewsWire

-Deal Valued in Excess of $32 Million -Eliminates Debt Associated with Avadel / Deerfield Agreement -Provides Non-Dilutive Cash Generation to Fund R&D  -Extends Runway Towards NDA Submission o...

1 year ago - GlobeNewsWire

Shares of Cerecor Inc. CERC, +2.96% rallied 17.5% in premarket trade Wednesday, after the biotech said the U.S.

1 year ago - Market Watch

ROCKVILLE, Md., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and ...

1 year ago - GlobeNewsWire

About CERC

Cerecor Inc., a biopharmaceutical company, focuses on development and commercialization of treatments for rare and orphan diseases. The company develops monosaccharide therapies for the treatment of congenital disorders of glycosylation, such as CERC-801, CERC-802, and CERC-803. It is also involved in the developing of CERC-007, an anti-IL-18 monoclonal antibody for the treatment of adult onset stills disease and multiple myeloma, as well as for the treatment of systemic juvenile idiopathic arthritis; CERC-006, an oral mTORC1/2 inhibitor to tre... [Read more...]

Industry
Biotechnology
IPO Date
Oct 15, 2015
Stock Exchange
NASDAQ
Ticker Symbol
CERC
Full Company Profile

Financial Performance

In 2020, Cerecor's revenue was $6.70 million, a decrease of -0.77% compared to the previous year's $6.75 million. Losses were -$63.50 million, 295.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Cerecor stock is "Buy." The 12-month stock price forecast is 6.25, which is an increase of 119.30% from the latest price.

Price Target
$6.25
(119.30% upside)
Analyst Consensus: Buy